1.Mäkelä, M, Rosén, M, Jamtvedt, G, Kristensen, FB, Mørland, B. Co-operation is strength: Joint achievements of the Nordic HTA centers. Michael. 2012;9:137–146.
2.Sampietro-Colom, L, Semberg, V, Dolors Estrada, M, et al.European joint assessments and coordination of findings and resources. Int J Technol Assess Health Care. 2002;8:321–360.
3.Kristensen, FB. Development of European HTA: from Vision to EUnetHTA. Michael. 2012;9:147–156.
4.Hailey, D, Marshall, D, Sampietro-Colom, L, et al.International collaboration in health technology assessment: a study of technologies used in management of osteoporosis. Health Policy. 1998;43:233–241.
5.Drummond, MF, Schwartz, JS, Jonsson, B, et al.Key principles for the improved conduct of health technology assessment for resource allocation decisions. Int J Technol Assess Health Care. 2008;24:244–258.
6.Rottingen, JA, Gerhardus, A, Garrido, MV. Future challenges for HTA in Europe. In: Garrido, MV, Kristensen, FB, Nielsen, CP, Busse, R, eds. Health technology assessment and health policy-making in Europe. Current status, challenges and potential. Observatory Studies Series No14, World Health Organization 2008, on behalf of the European Observatory on Health Systems and Policies.
7.Garrido, MV, Busse, R. Health technology assessment. An introduction to objectives, role of evidence, and structure in Europe. World Health Organization 2005, on behalf of the European Observatory on Health Systems and Policies.
8.Kristensen, FB, Gerhardus, A. Health technology assessments: what do differing conclusions tell us? BMJ. 2010;341:c5236
9.Kristensen, FB, Nielsen, CP, Chase, D, Lampe, K, Lee-Robin, SH, Mäkelä, M. What is health technology assessment? In: Velasco-Garrido, M, Kristensen, FB, Palmhøj Nielsen, C, Busse, R, eds. Health technology assessment and health policy-making in Europe-Current status, challenges and potential. Copenhagen: WHO Regional Office for Europe: 2008:53–78.
10.Henshall, C, Mardhani-Bayne, L, Fronsdal, KB, Klemp, M. On behalf of the HTAi Policy Forum. Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities. Int J Technol Assess Health Care. 2011;27:253–260.
11.Kristensen, FB, Lampe, K, Chase, D, et al.Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European Network for Health Technology Assessment, EUnetHTA. Int J Technol Assess Health Care. 2009; 25(Suppl 2):68–73.
12.Lampe, K, Mäkelä, M, Garrido, MV, et al.The HTA Core Model - A novel method for producing and reporting health technology assessments. Int J Technol Assess Health Care. 2009;25(Suppl 2):1–8.
13.Wild, C, Hinterreiter, G, Warmuth, M, Erdös, J. POP db: The EUnetHTA planned and ongoing projects database: Content and use. Poster at EUnetHTA conference in Gdansk/Poland, 8-9 December 2011.
15.Higgins, JPT, Green, S.Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. www.cochrane-handbook.org (accessed March 12, 2011).
16.Higgins, J, Altman, DG, Gotzsche, PC, et al.The Cochrane Collaborations tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
18.Guyatt, G, Oxman, AD, Akl, E, et al.GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–394.
20.Nachtnebel, A.Second-line chemotherapy with cabazitaxel (Jevtana®) for the treatment of castration-resistant metastatic prostate cancer. DSD: Horizon Scanning in Oncology. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment: 16; 2011.
21.Nachtnebel, A, Sotti, G, Vitale, A, Perrini, MR. Selective internal radiotherapy using yttrium-90 microspheres for primary and secondary liver malignancies. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; 2011.
22.Agency for Quality and Accreditation in Health Care, Department for Development, Research and Health Technology Assessment. The Croatian guideline for health technology assessment process and reporting, 1st ed.Zagreb. http://www.aaz.hr/main.php?ID=21. (accessed February 2011).
23.Zechmeister-Koss, I, Huić, M. Vascular endothelial growth factor inhibitors (anti-VEGF) for diabetic macular oedema. Decision support document Nr. 43. Wien; Zagreb: Ludwig Boltzmann Institut für Health Technology Assessment; Agencija za kvalitetu i akreditaciju u zdravstvu; 2011.
24.Zechmeister-Koss, I, Huić, M. Anti-Vascular-Endothelial-Growth-Factor (Anti-VEGF) bei diabetischem Makulaödem. Systematischer Review. Decision support document Nr. 43. Wien, Zagreb: Ludwig Boltzmann Institut für Health Technology Assessment; Agencija za kvalitetu i akreditaciju u zdravstvu; 2011.
25.Zechmeister-Koss, I, Huić, M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review. Br J Ophthalmol. 2012;96:167–178.
26.Shea, BJ, Grimshaw, JM, Wells, GA, et al.Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10.
27.The AGREE Collaboration. Appraisal of Guidelines for Research & Evaluation (AGREE) Instrument. www.agreecollaboration.org. (accessed December 18, 2011).
28.Sorenson, C.The role of HTA in coverage and pricing decision: A cross-country comparison. Euro Observer. 2009;11:1–12.
29.Kleijnen, S, George, E, Goulden, S, et al.Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions. Value Health. 2012;15:954–960.